Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (63)
May 30, 2005
-
Maurer's Healthcare Insight (62)
April 25, 2005
-
Maurer's Healthcare Insight (61)
March 28, 2005
-
Maurer's Healthcare Insight (60)
March 14, 2005
-
Maurer's Healthcare Insight (59)
December 6, 2004
-
Maurer's Healthcare Insight (58)
November 8, 2004
-
Maurer's Healthcare Insight (57)
October 11, 2004
-
Maurer's Healthcare Insight (56)
September 13, 2004
-
Maurer's Healthcare Insight (55)
July 26, 2004
-
Maurer's Healthcare Insight (54)
May 17, 2004
-
Maurer's Healthcare Insight (53)
April 19, 2004
-
Maurer's Healthcare Insight (52)
March 22, 2004
-
Maurer's Healthcare Insight (51)
March 1, 2004
-
Maurer's Healthcare Insight (50)
February 16, 2004
-
Maurer's Healthcare Insight (49)
January 26, 2004
-
Maurer's Healthcare Insight (48)
December 1, 2003
-
Maurer's Healthcare Insight (47)
November 3, 2003
-
Maurer's Healthcare Insight (46)
October 6, 2003
-
Maurer's Healthcare Insight (45)
September 8, 2003
-
Maurer's Healthcare Insight (44)
August 11, 2003
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…